Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada
Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada
复制标题
DOI：
10.1086/378304
复制
发表时间：
2003-10-15
影响因子：
11.8
通讯作者：
Matukas, L
中科院分区：
文献类型：
--
作者：
Knowles, SR;Phillips, EJ;Matukas, L
尽管缺乏疗效和药物不良反应的信息，但利巴韦林已被经验性地用于治疗严重急性呼吸综合征（SARS）。我们报告了 110 名接受利巴韦林治疗的疑似或疑似 SARS 患者的常见不良事件。 61% 的患者有溶血性贫血的证据，分别有 58% 和 46% 的患者报告有低钙血症和低镁血症。
Although information on efficacy and adverse drug reactions is lacking, ribavirin has been used empirically for the treatment of severe acute respiratory syndrome (SARS). We report common adverse events in 110 patients with suspected or probable SARS who were treated with ribavirin. Sixty-one percent of the patients had evidence of hemolytic anemia, and hypocalcemia and hypomagnesmia were reported in 58% and 46% of patients, respectively.